GLP-1
The 3-5 day post-escalation bloating peak could significantly impact performance
REDEFINE 1 (Garvey et al., NEJM 2025) is the only Phase 3 trial of an amylin + incretin co-administered combination, pairing cagrilintide 2.4 mg with semaglutide 2.4 mg
Phase III, PIONEER Program Multiple phase III efficacy trials have been fully published and/or presented in abstract form
Jastreboff, MD, PhD, Professor of Medicine at Yale University School of Medicine and Director of the Y-Weight Obesity Research Center, will discuss the pivotal Phase 3 TRIUMPH-1 trial evaluating the safety and efficacy of retatrutide in people with obesity
When reproducible physiology and biochemistry persist across years, modalities, and care settings, the question stops being is anything wrong? and becomes a governance one: Who owns the trigger for reevaluation when signals persist but dont fit a textbook pathway and where is that ownership documented so cases dont stall between handoffs
